Highlights

07-06 Laboratorio Erfo continues buyback, acquires 15,000 treasury shares AN
06-29 Laboratorio Farmaceutico Erfo buys back 14,000 treasury shares AN
06-22 Erfo Keeps Buying Back Stock, Repurchases 28,000 Shares AN
06-19 Laboratorio Farmaceutico Erfo S.p.A.'s Equity Buyback announced on December 18, 2024, has expired. CI
06-15 Laboratorio Farmaceutico Erfo acquires 15,000 treasury shares AN
05-21 Laboratorio Farmaceutico Erfo reports stable first-quarter revenue year-on-year AN
05-21 Laboratorio Farmaceutico Erfo Q1 EBITDA adj. EUR 0.5 mln RE
04-12 Laboratorio Farmaceutico Erfo S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
03-30 Laboratorio Farmaceutico Erfo posts triple-digit profit growth in 2025 AN
02-19 Erfo Increases EBITDA in 2025; Revenues More Than Double AN
02-19 Laboratorio Farmaceutico Erfo FY EBITDA EUR 2.0 Mln RE
11-21 Erfo Pharmaceutical Laboratory, revenues grow by 57% in nine months AN
11-21 Laboratorio Farmaceutico Erfo 9m Ebitda EUR 1.7 mln RE
25-09-29 Erfo Pharmaceutical Laboratory improves profits in the first half AN
25-09-29 Erfo H1 EBITDA EUR 1.2 mln RE
25-09-26 Laboratorio Farmaceutico Erfo S.p.A. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
25-08-28 Laboratorio Erfo Reports Double-Digit Growth in Revenue and EBITDA for First Half AN
25-08-28 Laboratorio Farmaceutico Erfo H1 ebitda eur 1.2 mln RE
25-07-14 Laboratorio Farmaceutico Erfo Purchases 13,000 Own Ordinary Shares AN
25-05-23 Laboratorio Erfo, revenues and EBITDA up significantly in the quarter AN
25-05-23 Erfo Q1 EBITDA EUR 0.5 Mln RE
25-05-21 Erfo presents Osteo-therapy, a nutraceutical supplement AN
25-04-01 Laboratorio Farmaceutico Erfo FY EBITDA Adj EUR 1.4 MlN RE
25-03-30 Laboratorio Farmaceutico Erfo S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
25-02-20 Erfo Pharmaceutical Laboratory, revenues stable in 2024; Ebitda drops AN
No results match your criteria